EA201201482A1 - Селективные ингибиторы интегрина - Google Patents

Селективные ингибиторы интегрина

Info

Publication number
EA201201482A1
EA201201482A1 EA201201482A EA201201482A EA201201482A1 EA 201201482 A1 EA201201482 A1 EA 201201482A1 EA 201201482 A EA201201482 A EA 201201482A EA 201201482 A EA201201482 A EA 201201482A EA 201201482 A1 EA201201482 A1 EA 201201482A1
Authority
EA
Eurasian Patent Office
Prior art keywords
integrine
inhibitors
selective
methods
selectively
Prior art date
Application number
EA201201482A
Other languages
English (en)
Inventor
Энтони Пепио
Гордон Фрэнсис
Теодор А. Йеднок
Алисса Чекериан
Брайан Тодд Уипк
Original Assignee
Элан Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Элан Фармасьютикалз, Инк. filed Critical Элан Фармасьютикалз, Инк.
Publication of EA201201482A1 publication Critical patent/EA201201482A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Это изобретение предусматривает способы для селективного антагонизирования гетеродимера интегрина α4β1 у субъекта, который в этом нуждается, а предпочтительно - у человека. Способы этого изобретения используют конъюгаты, включающие два или более мелкомолекулярных антагонистов α4β1, ковалентно присоединенных к биосовместимому полимеру. Эти способы селективного ингибирования α4β1 могут быть использованы для модулирования как нормальных, так и патологических биологических процессов, опосредованных, по меньшей мере, частично активностью α4β1.
EA201201482A 2010-04-30 2011-05-02 Селективные ингибиторы интегрина EA201201482A1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US33012210P 2010-04-30 2010-04-30
US39228810P 2010-10-12 2010-10-12
US201161516846P 2011-04-08 2011-04-08
PCT/US2011/034721 WO2011137418A1 (en) 2010-04-30 2011-05-02 Selective integrin inhibitors

Publications (1)

Publication Number Publication Date
EA201201482A1 true EA201201482A1 (ru) 2013-03-29

Family

ID=44260795

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201201482A EA201201482A1 (ru) 2010-04-30 2011-05-02 Селективные ингибиторы интегрина

Country Status (8)

Country Link
EP (1) EP2563405A1 (ru)
JP (1) JP2013525435A (ru)
KR (1) KR20130081651A (ru)
CN (1) CN102883750A (ru)
AU (1) AU2011245140A1 (ru)
CA (1) CA2797974A1 (ru)
EA (1) EA201201482A1 (ru)
WO (1) WO2011137418A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3722808A1 (en) * 2010-10-25 2020-10-14 Biogen MA Inc. Methods for determining differences in alpha-4 integrin activity by correlating differences in svcam and/or smadcam levels
EP3551034A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
TW201834710A (zh) 2016-12-14 2018-10-01 美商寶珍那提公司 以整合素抑制劑治療胃腸道疾病
WO2019246455A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
EP3870261B1 (en) 2019-12-13 2024-01-31 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101035563B (zh) * 2004-07-08 2012-03-28 艾伦药物公司 包括聚合物部分的多价vla-4拮抗剂
WO2006127584A1 (en) 2005-05-20 2006-11-30 Elan Pharmaceuticals, Inc. Imidazolone phenylalanine derivatives as vla-4 antagonists
CA2614200A1 (en) 2005-07-08 2007-01-18 Elan Pharmaceuticals, Inc. Preparation of polymer conjugates of therapeutic, agricultural, and food additive compounds
EP2019690A2 (en) 2006-05-22 2009-02-04 Elan Pharmaceuticals Inc. Preparation of polymer conjugates of vla-4 antagonists via a mitsunobu's reaction
EP2231185A4 (en) * 2007-12-07 2012-06-27 Elan Pharm Inc METHOD AND COMPOSITIONS FOR TREATING LIQUID TUMORS

Also Published As

Publication number Publication date
CA2797974A1 (en) 2011-11-03
AU2011245140A1 (en) 2012-12-20
JP2013525435A (ja) 2013-06-20
KR20130081651A (ko) 2013-07-17
EP2563405A1 (en) 2013-03-06
WO2011137418A1 (en) 2011-11-03
CN102883750A (zh) 2013-01-16

Similar Documents

Publication Publication Date Title
CY1122816T1 (el) Στοχοθετημενοι συνδετικοι παραγοντες εναντι β7-η1
CY1121327T1 (el) Τροποποιημενα αντισωματα anti-il-23p19
WO2012054638A3 (en) Nmr systems and methods for the detection of analytes
BR112013013790A2 (pt) compostos heterocíclos nitrogenosos 6,6-fundidos substituídos e usos dos mesmos
EA201170155A1 (ru) Специфические антагонисты рецептора fgf-r4
BR112013011090A2 (pt) suturas de autorretenção farmalógicas e métodos relacionados às mesmas
EA201270803A1 (ru) Тиоацетатные соединения, композиции на их основе и способы их применения
EA201691121A1 (ru) Гидроксиамидные соединения пиримидина в качестве ингибиторов деацетилаз белков и способы их применения
EA201170227A1 (ru) Имидазолкарбоксамиды
IL222252A0 (en) Methods, system and apparatus for the detection, diagnosis and treatment of biological rhythm disorders
EA201201482A1 (ru) Селективные ингибиторы интегрина
PH12015500114B1 (en) HUMAN ANTIBODIES TO GFRa3 AND METHODS OF USE THEREOF
WO2013033627A3 (en) Diagnosis and treatment of arthritis using epigenetics
EA201390821A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты и их применение
BR112013015592A8 (pt) derivados de biciclo-[3.2.1]-octilamida e usos dos mesmos
EA201590247A1 (ru) Антитела к siglec-15
BRPI0911491A2 (pt) métodos de monitoramento da modulação de atividade de quinase de receptor de fator de crescimento de fibroblasto e usos dos ditos métodos.
EE01079U1 (et) Territooriumi ja selle perimeetri j„lgimise ssteem
MA34057B1 (fr) Compositions et methodes pour le diagnostic et le traitement d'une tumeur
BR112013009294A2 (pt) componente dental, fixação dental, conjunto de implante dental e sistema de implante dental
DK2900279T3 (da) Grpr-antagonister til detektering, diagnose og behandling af grpr-positiv cancer
IT1391734B1 (it) Nuovi biomateriali, loro preparazione per elettrospinning e loro uso in campo biomedico e chirurgico.
IN2015DN03229A (ru)
ATE472998T1 (de) Kationische liposomale zubereitungen zur behandlung von rheumatoider arthritis
BR112015003032A2 (pt) anticorpos anti-jagged e métodos de utilização'.